Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41408-019-0245-1
Title: Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
Authors: Soekojo, Cinnie Yentia
Kim, Kihyun
Huang, Shang-Yi
Chim, Chor-Sang
Takezako, Naoki
Asaoku, Hideki
Kimura, Hideo
Kosugi, Hiroshi
Sakamoto, Junichi
Gopalakrishnan, Sathish Kumar
Nagarajan, Chandramouli
Wei, Yuan
Moorakonda, Rajesh
Lee, Shu Ling
Lee, Je Jung
Yoon, Sung-Soo
Kim, Jin Seok
Min, Chang Ki
Lee, Jae-Hoon
Durie, Brian
Chng, Wee Joo 
Keywords: Science & Technology
Life Sciences & Biomedicine
Oncology
Hematology
LOW-DOSE DEXAMETHASONE
LENALIDOMIDE
THALIDOMIDE
COHORT
Issue Date: 8-Oct-2019
Publisher: NATURE PUBLISHING GROUP
Citation: Soekojo, Cinnie Yentia, Kim, Kihyun, Huang, Shang-Yi, Chim, Chor-Sang, Takezako, Naoki, Asaoku, Hideki, Kimura, Hideo, Kosugi, Hiroshi, Sakamoto, Junichi, Gopalakrishnan, Sathish Kumar, Nagarajan, Chandramouli, Wei, Yuan, Moorakonda, Rajesh, Lee, Shu Ling, Lee, Je Jung, Yoon, Sung-Soo, Kim, Jin Seok, Min, Chang Ki, Lee, Jae-Hoon, Durie, Brian, Chng, Wee Joo (2019-10-08). Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. BLOOD CANCER JOURNAL 9 (10). ScholarBank@NUS Repository. https://doi.org/10.1038/s41408-019-0245-1
Abstract: Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/− cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex.
Source Title: BLOOD CANCER JOURNAL
URI: https://scholarbank.nus.edu.sg/handle/10635/229010
ISSN: 20445385
DOI: 10.1038/s41408-019-0245-1
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsedrefractory multiple myeloma (AMN001)-.pdfPublished version811.38 kBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

4
checked on Oct 1, 2022

Page view(s)

26
checked on Oct 6, 2022

Download(s)

5
checked on Oct 6, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.